2024 the latest weight loss peptide vials--CagriSema .pdf

Cagrisema(Cagrilintide/Semaglutide) is a combination of cagrilintide (a dual amylin and calcitonin receptor agonist) and semaglutide (a GLP-1 agonist). It is a long-term Effective combination therapy for the treatment of type 2 diabetes and obesity.

Cagrisema’s clinical trial results show that it exhibits superior effects on weight loss and blood sugar reduction compared with cagrilintide or semaglutide alone. In addition, cagrisema can significantly reduce patients’ glycosylated hemoglobin (HbA1c) levels.

1. www.aea.ltd
APICMO&CDMOManufacturer
Email:[email protected]
2024thelatestweightlosspeptidevials--CagriSema
Content
Properties......................................................................................................................1
WhatisCagriSema.........................................................................................................2
HowdoCagriSemawork................................................................................................2
WhatarethepotentialadvantagesofCagriSema..........................................................3
IsCagriSemasafe............................................................................................................4
CagriSemaVSTirzepatide...............................................................................................5
CagriSemaVSDulaglutide.......................................................................................................7
AreamycretinandCagriSemathesamemedicine............................................................9
WheretobuyCagriSema................................................................................................9
FAQ.................................................................................................................................10

2. www.aea.ltd
APICMO&CDMOManufacturer
Email:[email protected]
Properties:
Cagrisema(Cagrilintide/Semaglutide)isacombinationofcagrilintide(adualamylinandcalcitoninreceptoragonist)andsemaglutide(aGLP-1
agonist).Itisalong-termEffectivecombinationtherapyforthetreatmentoftype2diabetesandobesity.
Cagrisema’sclinicaltrialresultsshowthatitexhibitssuperioreffectsonweightlossandbloodsugarreductioncomparedwithcagrilintideor
semaglutidealone.Inaddition,cagrisemacansignificantlyreducepatients’glycosylatedhemoglobin(HbA1c)levels.
Therearemanypeptideproductsforweightlossinmarketnow,whichalsocanbeprovidedbyAea.ltdandacceptthecustomizedservice:
ProductName CASNumber Availability
Semaglutide 910463-68-2 √
Tirzepatide 2023788-19-2 √
Retatrutide 2381089-83-2 √
Cagrilintide 1415456-99-3 √
Dulaglutide 923950-08-7 √
Cagrisema Cagrilintide+Semaglutide √

3. www.aea.ltd
APICMO&CDMOManufacturer
Email:[email protected]
Liraglutide 204656-20-2 √
Survodutide 2805997-46-8 √
Ecnoglutide 2459531-73-6 √
1.WhatIsCagrisema?
Cagrisema(Cagrilintide/Semaglutide)isacombinationofcagrilintide(adualamylinandcalcitoninreceptoragonist)andsemaglutide(aGLP-1
agonist).Itisalong-termEffectivecombinationtherapyforthetreatmentoftype2diabetesandobesity.
Cagrisema’sclinicaltrialresultsshowthatitexhibitssuperioreffectsonweightlossandbloodsugarreductioncomparedwithcagrilintideor
semaglutidealone.Inaddition,cagrisemacansignificantlyreducepatients’glycosylatedhemoglobin(HbA1c)levels.
2.HowDoesCagrisemaWork?
Cagrisemaisanoveldual-actiontherapydesignedtoeffectivelytreattype2diabetesandobesitybycombiningtwocomplementary
pharmaceuticalingredients,semaglutideandcagrilintide.
Semaglutideisalong-actingGLP-1receptoragonistthatmimicstheeffectsofthenaturalintestinalhormoneGLP-1,slowingdigestion,
enhancingsatiety,andloweringbloodglucosebyincreasingglucose-dependentinsulinsecretion.Cagrilintideisalong-actingamylinanalogue
thatactsasadualagonist,actingonamylin-likepeptidesandcalcitoninreceptors,andmimicstheeffectsofamylintofurtherpromotesatiety
andreduceintestinalsensitivity.Absorptionofsugar.Therefore,itmayenhancetheweightlosseffectsofsemaglutide.

4. www.aea.ltd
APICMO&CDMOManufacturer
Email:[email protected]
Cagrisemaisuniqueinthatitcombinestheadvantagesofsemaglutideandcaglilintidetoformapowerfulcombinationtreatment.Semaglutide
startswithbloodsugarcontrolandreducessugarintakeandabsorption.Cagrilintidestartswithappetiteregulation,reducingfoodintakeand
increasingenergyexpenditure.Thistwo-prongedmechanismenablescagrisematobringmorecomprehensivetherapeuticeffectstopatientswith
type2diabetesandobesity.
3.WhatarethepotentialadvantagesofCagrisema?
①Effectivebloodsugarcontrol:Cagrisemahasshownsignificantefficacyinreducingbloodsugarlevelsinclinicaltrials.TheTrifectatrial
showedthatcagrisemasignificantlyreducedHbA1clevelsby1.8%comparedwithplacebo,whileintheDURATION-6trial,cagrisemareduced
HbA1cby1.7%comparedwithdulaglutide.Fromthis,cagrisemasignificantlyreducedHbA1clevels,akeyindicatoroflong-termbloodsugar
control.
②SignificantWeightLoss:Cagrisema’sdualmechanismofactionpromotesweightlossbyreducingappetite,increasingsatiety,and
increasingenergyexpenditure.IntheSTEPobesitytrial,cagrisemaresultedinanaverageweightlossof12.1%andsignificantimprovementsin
cardiometabolicmarkerscomparedwithplacebo.IntheRESET-Otrial,cagrisemaresultedinanaverageweightlossof16.4%andasignificant
reductioninbodyfatpercentageandwaistcircumferencecomparedtoplacebo.
③Improvedcardiovascularhealth:Cagrisema’spositiveeffectsonbloodsugarandweightmanagementmayalsotranslateintoimproved
cardiovascularhealth.Studiesshowthatcagrisemacanlowerbloodpressure,improvebloodlipids,andreducetheriskofcardiovascularevents.
Moreover,thefollowingexperimentalresultsarethecomparativeadvantagesofcagrisemacomparedwiththeuseofcaglilintideorsemaglutide
alone:
Measure Cagrisema Semaglutide Cagrilinitide

5. www.aea.ltd
APICMO&CDMOManufacturer
Email:[email protected]
Numberofparticipants 31 31 30
AveragedecreaseinA1C 2.2% 1.8% 0.9%
PercentageofparticipantswithanA1C≤6.5% 75% 48% 17%
Averagedecreaseinbodyweight 15.6% 5.1% 8.1%
Averageincreaseintimeinrange 43% 43.6% 14.8%
4.IsCagrisemasafe?
Cagrisemaisstillinclinicaltrialsandthefullextentofitssafetyprofilehasnotyetbeenfullydetermined.However,basedonclinicaltrialdata
todate,themainsideeffectsaregastrointestinaleffects,suchasnausea,vomiting,diarrheaorconstipation.Thesesideeffectsareusuallymildto
moderateandusuallysubsidewithinafewdaysorweeksafterstartingtreatment.Insomecases,moreseriousgastrointestinalsideeffectsmay
occur,suchaspancreatitis,gallbladderinflammation,biliarystones,etc.Theremayalsobepotentialsideeffectssuchasinjectionsitereactions,
headaches,andfatigue.
However,currentclinicaldatadonotindicategrade2(lessthan54mg/dL)orgrade3hypoglycemia(severehypoglycemiarequiringhelpfrom
anotherperson).TheseresultsindicatethatcagrisemaiscurrentlysafeandthatgastrointestinalsideeffectsaresimilartootherGLP-1drugs.

6. www.aea.ltd
APICMO&CDMOManufacturer
Email:[email protected]
Ifyouareconsideringbuyingcagrisemapowder,foryourhealthandsafety,pleasestillpayattentiontothequalityofcagrisemawhenpurchasing
andusingit.Pleaseensurethatthepowderyoupurchasemeetshighqualitystandards.Aea.ltdiscommittedtoprovidingyouwithhighquality
cagrisemapowdertominimizepotentialsideeffects.
5.CagrisemaVSTirzepatide
IntheREDEFINE4trial,atotalof800patientsparticipatedina72-weektrialcomparingtheefficacyofcagrisemawithtirzepatide.The
followingtableistheexperimentaldataresults:
Outcome CagriSema Tesiptatide
WeightLoss(changefrombaselineat72weeks) -16.40% -10.60%
HbA1cReduction(changefrombaselineat72weeks) -1.80% -1.30%
FastingPlasmaGlucoseReduction(changefrombaselineat72weeks) -54mg/dL -41mg/dL
PostprandialGlucoseReduction(changefrombaselineat72weeks) -70mg/dL -52mg/dL
Thistrialshowsthatsagrisemaismoreeffectivethantirzepatideintermsofweightloss.
Then,continuingtostudythetwo,wecandiscoverotherdifferences:

7. www.aea.ltd
APICMO&CDMOManufacturer
Email:[email protected]
Feature Cagrisema Tirzepatide(Mounjaro)
MechanismofAction DualGLP-1/CGRPagonist DualGLP-1/GIPagonist
ModeofAction:
Semaglutide(GLP-1agonist)stimulatesinsulinsecretion,
delaysgastricemptying,andsuppressesglucagon
secretion.
Cagrilintide(CGRPagonist)reducesappetiteand
increasesenergyexpenditure.
Tirzepatide(dualGLP-1/GIPagonist)stimulatesinsulin
secretion,delaysgastricemptying,suppressesglucagon
secretion,andenhancesglucose-dependent
insulinotropicpolypeptide(GIP)secretion.
Administration Subcutaneousinjection Subcutaneousinjection
Dosage 0.5mgor1.0mgonceweekly 2.5mgor5.0mgonceweekly
Indications Type2diabetesandobesity Type2diabetesandobesity
Safety
Generallywell-tolerated;gastrointestinalsideeffects
(nausea,vomiting,diarrhea,constipation)aremost
common
Generallywell-tolerated;gastrointestinalsideeffects
(nausea,vomiting,diarrhea,constipation)aremost
common

8. www.aea.ltd
APICMO&CDMOManufacturer
Email:[email protected]
Advantages
SuperiorweightlossefficacycomparedtoTirzepatidein
clinicaltrials.Dual-actionmechanismtargetingboth
GLP-1andCGRPreceptorsmayprovidebroaderbenefits.
Approvedandavailableforclinicaluse.Demonstrated
efficacyinbothweightlossandbloodsugarcontrol.
Legalstatus Notyetcommerciallyavailable ApprovedandavailableintheUnitedStates
Selectionsuggestions:
①PersonalGoals:Choosingwhichpeptidetousedependsonyourpersonalweightlossandhealthgoals.Ifyouwanttoachievefasterweight
lossresultsintheshortterm,cagrisemamaybeasuitableoptionforyou.Ifyouareadiabeticorsomeonewhopaysmoreattentiontoblood
sugarcontrol,thenyoucanchoosetirzepatide,anotherpeptidefromAea.ltd,whichmaybemoresuitableforyou.
②Safetyconsiderations:Understandthatindividualsmayresponddifferentlytodifferentpeptides,sobeforeconsideringuse,theirsafetyand
potentialsideeffectsshouldbeevaluatedandusedonlyinappropriatedosesandcircumstances,andunderthesupervisionofamedical
professionalUseunderguidance.
③QualityandSource:Choosingqualityproductsandtrustworthysuppliersiscrucialtoensureyouareusingpure,safeproducts.Aea.ltdaimsto
providethehighestqualitycagrisemaandtirzepatidepowders,nomatterwhichpeptideyouultimatelychoose,Aea.ltdisareliablesourceyou
cantrust.
6.CagrisemaVSDulaglutide

9. www.aea.ltd
APICMO&CDMOManufacturer
Email:[email protected]
Feature Cagrisema Dulaglutide
Type CombinationGLP-1receptoragonistandamylinanalogueGLP-1receptoragonist
Mechanismof
action
BindstoGLP-1andamylinreceptors,stimulatinginsulin
secretion,suppressingglucagonsecretion,anddelaying
gastricemptying
BindstoGLP-1receptors,stimulatinginsulinsecretion,
suppressingglucagonsecretion,anddelayinggastricemptying
Dosage 2.4mgsubcutaneousinjectiononceweekly 0.75mgor1.5mgsubcutaneousinjectiononceweekly
Indications type2diabetesandobesity type2diabetes
Advantages
ActsonbothGLP-1andamylinreceptors,potentially
offeringstrongerglycemicandweightlosseffects.
Earlystudiesshowpromisingresultsforweightloss.
FDA-approved,withawell-establishedsafetyprofile.
Demonstratedefficacyinloweringbloodsugarlevels.
Canreducethenumberofinjections.
Safety Nolong-termsafetydatayet Extensivelong-termsafetydataavailable

10. www.aea.ltd
APICMO&CDMOManufacturer
Email:[email protected]
7.AreAmycretinandCagrisemathesamemedicine?
AmycretinandCagrisemaarenotthesamedrug,buttheyarebothdrugsthattreattype2diabetesandobesity.Therearesimilaritiesand
differencesbetweenthem.
Similarities:
①Theyaredual-actiondrugsthatcombinetheeffectsofaGLP-1receptoragonistandanamyloidpeptidereceptoragonist.
②Theybothhavethepotentialtopromoteweightlossandimprovebloodsugarcontrol.
Differences:
①Amycretinisasinglemolecule,whilecagrisemaisadualdrugconsistingofsemaglutide(GLP-1receptoragonist)andcagrilintide(amyloid
peptidereceptoragonist).
②Amycretinisstillinclinicaltrials,whilecagrisemaisstillindevelopmentandhasnotyetbeenapprovedbytheFDA.
③Amycretinisadailyoralmedication,whilecagrisemaisasubcutaneousinjection.
Inaddition,cagrisemaiscurrentlyinamoreadvancedstageofdevelopmentthanAmycretin,butbothdrugsrequirefurtherstudy.
8.WhereToBuyCagrisema?

11. www.aea.ltd
APICMO&CDMOManufacturer
Email:[email protected]
Aea.ltdisyourbestchoicewhenshoppingonline.Aea.ltdfocusesonprovidinghigh-qualitycagrisemarawpowderandlyophilizedpowderin
vial.Inbothformsweguaranteethehighestqualitycagrisemaproducts.Toensureyoursafety,werecommendthatyoucarefullyscreenand
compareextensivelytoensurethatthechoiceyoumakeisasreliableasAea.ltd.
FAQ:
YouMightAlsoBeConcernedAboutTheseIssues:
1.Doescagrisemwork?
2.Whatisthemostpowerfulpeptideforweightloss?
3.Whatiscagrisemusedfor?
4.IsCagriSemaapproved?
5.WhatarethesideeffectsofthedrugCagriSema?
6.wherecanIbuyhighqualitycagrisemonline?
7.Iscagrisemsafeforlong-termuse?
8.IsCagriSemaphase2diabetes?

12. www.aea.ltd
APICMO&CDMOManufacturer
Email:[email protected]
9.WhatisthedifferencebetweenamycretinandCagriSema?
10.Whocannotusecagrisem?
11.HowisCagriSemaadministered?
12.Iscagrisemlegal?
Asforthesequestions,pleasegototheofficialwebsiteoforiginaldrugandseefullPrescribingInformationandMedicationGuide,especially
forpersonaluse,pleaseusecagrisemaundertheguideofdoctor.